Advertisement

Molecular imaging and therapy of somatostatin receptor positive tumors

      Highlights

      • 68Ga DOTATATE PET is far superior than 111In-pentetreotide SPECT/CT in imaging of somatostatin receptor positive tumors.
      • 68Ga DOTATATE PET is now the preferred imaging modality for initial diagnosis, and selection of patients for PRRT
      • 68Ga DOTATATE PET use in other SSTR positive tumors such as meningioma, ENB, and pheochromocytoma is object of ongoing research.
      • SSTR targeted radionucleotide therapy is already approved for advanced GEP-NETs and has a potential of use in other SSTR positive neoplasms.

      Abstract

      Somatostatin receptors (SSTR) are upregulated in the cells of origin that define numerous neuroendocrine neoplasms. PET imaging with 68Ga-DOTATATE allows specific targeting of SSTR2A, a single species of SSTR receptor, which is commonly overexpressed in a variety of gastroenteropancreatic neuroendocrine tumors, as well as pulmonary carcinoid and head and neck tumors. Due to more specific targeting of SSTR2 as well as lower radiation dose, shorter study length, ability to quantify uptake, and lower cost, 68Ga-DOTATATE has demonstrated superior imaging attributes when compared to 111In-pentetreotide. As with any novel imaging modality, dedicated training, increasing experience and staying up-to-date with scientific publications are required to provide optimal patient care. The purpose of this review is to summarize the current state of the art in SSTR-targeted molecular imaging and discuss ongoing and future potential diagnostic and therapeutic applications.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Imaging
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Deppen S.A.
        • Blume J.
        • Bobbey A.J.
        • Shah C.
        • Graham M.M.
        • Lee P.
        • et al.
        68Ga-DOTATATE compared with 111In-DTPA-octreotide and conventional imaging for pulmonary and gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis.
        J Nucl Med. 2016; 57: 872-878
        • Deroose C.M.
        • Hindie E.
        • Kebebew E.
        • Goichot B.
        • Pacak K.
        • Taieb D.
        • et al.
        Molecular imaging of gastroenteropancreatic neuroendocrine tumors: current status and future directions.
        J Nucl Med. 2016; 57: 1949-1956
        • Walker R.C.
        • Smith G.T.
        • Liu E.
        • Moore B.
        • Clanton J.
        • Stabin M.
        Measured human dosimetry of 68Ga-DOTATATE.
        J Nucl Med. 2013; 54: 855-860
        • Krenning E.P.
        • Bakker W.H.
        • Kooij P.P.
        • Breeman W.A.
        • Oei H.Y.
        • de Jong M.
        • et al.
        Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide.
        J Nucl Med. 1992; 33: 652-658
        • Hofman M.S.
        • Lau W.F.
        • Hicks R.J.
        Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation.
        Radiographics. 2015; 35: 500-516
        • Geijer H.
        • Breimer L.H.
        Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis.
        Eur J Nucl Med Mol Imaging. 2013; 40: 1770-1780
        • Sharma P.
        • Singh H.
        • Bal C.
        • Kumar R.
        PET/CT imaging of neuroendocrine tumors with (68)Gallium-labeled somatostatin analogues: an overview and single institutional experience from India.
        Indian J Nucl Med. 2014; 29: 2-12
        • Sanli Y.
        • Garg I.
        • Kandathil A.
        • Kendi T.
        • Zanetti M.J.B.
        • Kuyumcu S.
        • et al.
        Neuroendocrine tumor diagnosis and management: (68)Ga-DOTATATE PET/CT.
        AJR Am J Roentgenol. 2018; 211: 267-277
        • Graham M.M.
        • Gu X.
        • Ginader T.
        • Breheny P.
        • Sunderland J.J.
        (68)Ga-DOTATOC imaging of neuroendocrine tumors: a systematic review and metaanalysis.
        J Nucl Med. 2017; 58: 1452-1458
        • Bodei L.
        • Ambrosini V.
        • Herrmann K.
        • Modlin I.
        Current concepts in (68)Ga-DOTATATE imaging of neuroendocrine neoplasms: interpretation, biodistribution, dosimetry, and molecular strategies.
        J Nucl Med. 2017; 58: 1718-1726
        • Shastry M.
        • Kayani I.
        • Wild D.
        • Caplin M.
        • Visvikis D.
        • Gacinovic S.
        • et al.
        Distribution pattern of 68Ga-DOTATATE in disease-free patients.
        Nucl Med Commun. 2010; 31: 1025-1032
        • Virgolini I.
        • Ambrosini V.
        • Bomanji J.B.
        • Baum R.P.
        • Fanti S.
        • Gabriel M.
        • et al.
        Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE.
        Eur J Nucl Med Mol Imaging. 2010; 37: 2004-2010
        • Virgolini I.
        • Gabriel M.
        • Kroiss A.
        • von Guggenberg E.
        • Prommegger R.
        • Warwitz B.
        • et al.
        Current knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumours.
        Eur J Nucl Med Mol Imaging. 2016; 43: 2072-2083
        • Hofman M.S.
        • Kong G.
        • Neels O.C.
        • Eu P.
        • Hong E.
        • Hicks R.J.
        High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours.
        J Med Imaging Radiat Oncol. 2012; 56: 40-47
        • Cives M.
        • Strosberg J.R.
        Gastroenteropancreatic neuroendocrine tumors.
        CA Cancer J Clin. 2018; 68: 471-487
        • Dasari A.
        • Shen C.
        • Halperin D.
        • Zhao B.
        • Zhou S.
        • Xu Y.
        • et al.
        Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States.
        JAMA Oncol. 2017; 3: 1335-1342
        • Williams E.D.
        • Sandler M.
        The classification of carcinoid tum ours.
        Lancet. 1963; 1: 238-239
        • Halfdanarson T.R.
        • Rabe K.G.
        • Rubin J.
        • Petersen G.M.
        Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival.
        Ann Oncol. 2008; 19: 1727-1733
        • Rindi G.
        • Kloppel G.
        • Alhman H.
        • Caplin M.
        • Couvelard A.
        • de Herder W.W.
        • et al.
        TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.
        Virchows Arch. 2006; 449: 395-401
        • Paulson E.K.
        • McDermott V.G.
        • Keogan M.T.
        • DeLong D.M.
        • Frederick M.G.
        • Nelson R.C.
        Carcinoid metastases to the liver: role of triple-phase helical CT.
        Radiology. 1998; 206: 143-150
        • Sadowski S.M.
        • Neychev V.
        • Millo C.
        • Shih J.
        • Nilubol N.
        • Herscovitch P.
        • et al.
        Prospective study of 68Ga-DOTATATE positron emission tomography/computed tomography for detecting gastro-Entero-pancreatic neuroendocrine tumors and unknown primary sites.
        J Clin Oncol. 2016; 34: 588-596
        • Shell J.
        • Keutgen X.M.
        • Millo C.
        • Nilubol N.
        • Patel D.
        • Sadowski S.
        • et al.
        68-Gallium DOTATATE scanning in symptomatic patients with negative anatomic imaging but suspected neuroendocrine tumor.
        Int J Endocr Oncol. 2018; 5: IJE04
        • Hope T.A.
        • Bergsland E.K.
        • Bozkurt M.F.
        • Graham M.
        • Heaney A.P.
        • Herrmann K.
        • et al.
        Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors.
        J Nucl Med. 2018; 59: 66-74
        • Yazawa T.
        Recent advances in histogenesis research of lung neuroendocrine cancers: evidence obtained from functional analyses of primitive neural/neuroendocrine cell-specific transcription factors.
        Pathol Int. 2015; 65: 277-285
        • Travis W.D.
        Pathology and diagnosis of neuroendocrine tumors: lung neuroendocrine.
        Thorac Surg Clin. 2014; 24: 257-266
        • Govindan R.
        • Page N.
        • Morgensztern D.
        • Read W.
        • Tierney R.
        • Vlahiotis A.
        • et al.
        Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.
        J Clin Oncol. 2006; 24: 4539-4544
        • Kayani I.
        • Conry B.G.
        • Groves A.M.
        • Win T.
        • Dickson J.
        • Caplin M.
        • et al.
        A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors.
        J Nucl Med. 2009; 50: 1927-1932
        • Lococo F.
        • Cesario A.
        • Paci M.
        • Filice A.
        • Versari A.
        • Rapicetta C.
        • et al.
        PET/CT assessment of neuroendocrine tumors of the lung with special emphasis on bronchial carcinoids.
        Tumour Biol. 2014; 35: 8369-8377
        • Benson R.E.
        • Rosado-de-Christenson M.L.
        • Martinez-Jimenez S.
        • Kunin J.R.
        • Pettavel P.P.
        Spectrum of pulmonary neuroendocrine proliferations and neoplasms.
        Radiographics. 2013; 33: 1631-1649
        • Ambrosini V.
        • Nicolini S.
        • Caroli P.
        • Nanni C.
        • Massaro A.
        • Marzola M.C.
        • et al.
        PET/CT imaging in different types of lung cancer: an overview.
        Eur J Radiol. 2012; 81: 988-1001
        • Ambrosini V.
        • Castellucci P.
        • Rubello D.
        • Nanni C.
        • Musto A.
        • Allegri V.
        • et al.
        68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid.
        Nucl Med Commun. 2009; 30: 281-286
        • Fishbein L.
        Pheochromocytoma and paraganglioma: genetics, diagnosis, and treatment.
        Hematol Oncol Clin North Am. 2016; 30: 135-150
        • Kasperlik-Zaluska A.A.
        • Roslonowska E.
        • Slowinska-Srzednicka J.
        • Otto M.
        • Cichocki A.
        • Cwikla J.
        • et al.
        1,111 patients with adrenal incidentalomas observed at a single endocrinological center: incidence of chromaffin tumors.
        Ann N Y Acad Sci. 2006; 1073: 38-46
        • Williams V.C.
        • Lucas J.
        • Babcock M.A.
        • Gutmann D.H.
        • Korf B.
        • Maria B.L.
        Neurofibromatosis type 1 revisited.
        Pediatrics. 2009; 123: 124-133
        • Cohen D.L.
        • Fraker D.
        • Townsend R.R.
        Lack of symptoms in patients with histologic evidence of pheochromocytoma: a diagnostic challenge.
        Ann N Y Acad Sci. 2006; 1073: 47-51
        • Lenders J.W.
        • Duh Q.Y.
        • Eisenhofer G.
        • Gimenez-Roqueplo A.P.
        • Grebe S.K.
        • Murad M.H.
        • et al.
        Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline.
        J Clin Endocrinol Metab. 2014; 99: 1915-1942
        • Alrezk R.
        • Suarez A.
        • Tena I.
        • Pacak K.
        Update of Pheochromocytoma syndromes: genetics, biochemical evaluation, and imaging.
        Front Endocrinol (Lausanne). 2018; 9: 515
        • Janssen I.
        • Blanchet E.M.
        • Adams K.
        • Chen C.C.
        • Millo C.M.
        • Herscovitch P.
        • et al.
        Superiority of [68Ga]-DOTATATE PET/CT to other functional imaging modalities in the localization of SDHB-associated metastatic pheochromocytoma and paraganglioma.
        Clin Cancer Res. 2015; 21: 3888-3895
        • Janssen I.
        • Chen C.C.
        • Zhuang Z.
        • Millo C.M.
        • Wolf K.I.
        • Ling A.
        • et al.
        Functional imaging signature of patients presenting with polycythemia/paraganglioma syndromes.
        J Nucl Med. 2017; 58: 1236-1242
        • Jha A.
        • Ling A.
        • Millo C.
        • Gupta G.
        • Viana B.
        • Lin F.I.
        • et al.
        Superiority of (68)Ga-DOTATATE over (18)F-FDG and anatomic imaging in the detection of succinate dehydrogenase mutation (SDHx)-related pheochromocytoma and paraganglioma in the pediatric population.
        Eur J Nucl Med Mol Imaging. 2018; 45: 787-797
        • Kunz W.G.
        • Jungblut L.M.
        • Kazmierczak P.M.
        • Vettermann F.J.
        • Bollenbacher A.
        • Tonn J.C.
        • et al.
        Improved detection of transosseous meningiomas using (68)Ga-DOTATATE PET/CT compared with contrast-enhanced MRI.
        J Nucl Med. 2017; 58: 1580-1587
        • Makis W.
        • McCann K.
        • McEwan A.J.
        Esthesioneuroblastoma (olfactory neuroblastoma) treated with 111In-octreotide and 177Lu-DOTATATE PRRT.
        Clin Nucl Med. 2015; 40: 317-321
        • Sabongi J.G.
        • Goncalves M.C.
        • Alves C.D.
        • Alves J.
        • Scapulatempo-Neto C.
        • Moriguchi S.M.
        Lutetium 177-DOTA-TATE therapy for esthesioneuroblastoma: a case report.
        Exp Ther Med. 2016; 12: 3078-3082
        • Schneider J.R.
        • Shatzkes D.R.
        • Scharf S.C.
        • Tham T.M.
        • Kulason K.O.
        • Buteau F.A.
        • et al.
        Neuroradiological and neuropathological changes after 177Lu-Octreotate peptide receptor radionuclide therapy of refractory esthesioneuroblastoma.
        Oper Neurosurg (Hagerstown). 2018; 15: 100-109
        • Papadakis G.Z.
        • Millo C.
        • Jassel I.S.
        • Bagci U.
        • Sadowski S.M.
        • Karantanas A.H.
        • et al.
        18F-FDG and 68Ga-DOTATATE PET/CT in von Hippel-Lindau disease-associated retinal hemangioblastoma.
        Clin Nucl Med. 2017; 42: 189-190
        • Chan M.
        • Hsiao E.
        Incidental finding of cerebellar medulloblastoma on 68Ga-DOTATATE PET/CT in a patient with appendiceal carcinoid.
        Clin Nucl Med. 2016; 41: 886-887
        • Group NGSiPS
        • Toledo R.A.
        • Burnichon N.
        • Cascon A.
        • Benn D.E.
        • Bayley J.P.
        • et al.
        Consensus statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas.
        Nat Rev Endocrinol. 2017; 13: 233-247
        • Chetty R.
        Familial paraganglioma syndromes.
        J Clin Pathol. 2010; 63: 488-491
        • Barbolosi D.
        • Crona J.
        • Serre R.
        • Pacak K.
        • Taieb D.
        Mathematical modeling of disease dynamics in SDHB- and SDHD-related paraganglioma: further step in understanding hereditary tumor differences and future therapeutic strategies.
        PLoS One. 2018; 13e0201303
        • Janssen I.
        • Chen C.C.
        • Taieb D.
        • Patronas N.J.
        • Millo C.M.
        • Adams K.T.
        • et al.
        68Ga-DOTATATE PET/CT in the localization of head and neck paragangliomas compared with other functional imaging modalities and CT/MRI.
        J Nucl Med. 2016; 57: 186-191
        • Papadakis G.Z.
        • Bagci U.
        • Sadowski S.M.
        • Patronas N.J.
        • Stratakis C.A.
        Ectopic ACTH and CRH co-secreting tumor localized by 68Ga-DOTA-TATE PET/CT.
        Clin Nucl Med. 2015; 40: 576-578
        • Wang H.
        • Hou B.
        • Lu L.
        • Feng M.
        • Zang J.
        • Yao S.
        • et al.
        PET/MRI in the diagnosis of hormone-producing pituitary microadenoma: a prospective pilot study.
        J Nucl Med. 2018; 59: 523-528
        • Cwikla J.B.
        • Sankowski A.
        • Seklecka N.
        • Buscombe J.R.
        • Nasierowska-Guttmejer A.
        • Jeziorski K.G.
        • et al.
        Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study.
        Ann Oncol. 2010; 21: 787-794
        • Strosberg J.
        • El-Haddad G.
        • Wolin E.
        • Hendifar A.
        • Yao J.
        • Chasen B.
        • et al.
        Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors.
        N Engl J Med. 2017; 376: 125-135
        • Pusceddu S.
        • Buzzoni R.
        • de Braud F.
        The underestimated role of somatostatin analogs in the NETTER-1 trial.
        Future Oncol. 2017; 13: 1287-1289
        • Boucher J.E.
        • Sommers R.
        Targeted therapy: new radiolabeled somatostatin analogs to treat gastroenteropancreatic neuroendocrine tumors.
        Clin J Oncol Nurs. 2018; 22: 565-568
        • Sadowski S.M.
        • Millo C.
        • Neychev V.
        • Aufforth R.
        • Keutgen X.
        • Glanville J.
        • et al.
        Feasibility of radio-guided surgery with (6)(8)Gallium-DOTATATE in patients with gastro-entero-pancreatic neuroendocrine tumors.
        Ann Surg Oncol. 2015; 22: S676-S682
        • El Lakis M.
        • Gianakou A.
        • Nockel P.
        • Wiseman D.
        • Tirosh A.
        • Quezado M.A.
        • et al.
        Radioguided surgery with gallium 68 Dotatate for patients with neuroendocrine tumors.
        JAMA Surg. 2019; 154: 40-45